Non-Hodgkin Lymphoma

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

Clémentine Sarkozy, MD, PhD, and Carla Casulo, MD, detail the evolution of lymphoma management strategies.

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

Panelists discuss how unmet needs in cutaneous T-cell lymphoma include the lack of a cure, the need for better biomarkers for early diagnosis and treatment response prediction; improving patients' quality of life by managing symptoms, such as itch; advancing understanding of disease biology to develop effective targeted therapies, such as cell therapy; and the importance of multidisciplinary care and clinical trial participation.

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

Panelists discuss how stem cell transplantation is considered primarily for younger patients or aggressive CTCL variants, balancing timing, remission status, and potential risks, while also emphasizing the value of early referral and specialized guidance for advanced disease.

Panelists discuss how decisions about reintroducing previous therapies for CTCL are based on prior tolerance, current disease state, and the reason for stopping treatment, with flexibility to recycle effective agents when appropriate.

Stefano Luminari, MD, discusses unmet needs for patients with follicular lymphoma, updated data from the ELM-2 trial, and infection risk management advice.

Panelists discuss how to differentiate Mogamulizumab-associated rash from CTCL using clinical clues, biopsy findings, and molecular studies, and how treatment may be modified based on rash severity and characteristics.

Panelists discuss how to sequence and personalize therapy for Sézary syndrome, with mogamulizumab often used as first-line treatment due to potential for durable remission, followed by HDAC inhibitors, photopheresis, or alemtuzumab depending on disease progression and transplant planning.

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.